Micropos Medical Celebrates First Clinical Treatments Using Raypilot System at Johns Hopkins

Micropos Medical Celebrates a Pivotal Moment in Prostate Cancer Treatment

GOTHENBURG, Sweden — In an exciting advancement for cancer treatment technology, Micropos Medical AB has officially announced that the first five patients in the United States have received treatments utilizing the Raypilot® System. This noteworthy achievement took place at Johns Hopkins Medicine, renowned for its exceptional healthcare services and academic excellence globally.

This collaboration between Micropos Medical and Johns Hopkins represents a significant milestone that underscores a growing interest in cutting-edge technologies aimed at enhancing precision in radiotherapy, especially for prostate cancer patients. Kauko Haapasaari, Project Leader in the USA for Micropos Medical, expressed his enthusiasm about this collaboration, stating, "This is an important milestone for Micropos Medical. Having Johns Hopkins Medicine evaluate new technology and clinical workflows that enhance treatment accuracy while minimizing side effects is immensely significant."

The introduction of the Raypilot® System into clinical practice at Johns Hopkins signals an essential step towards improving the quality of life for patients undergoing radiotherapy for prostate cancer. The joint efforts of both the Johns Hopkins and Micropos teams are a testament to their commitment to enhancing patient care.

The Raypilot® System: Enhancing Treatment Precision

With the goal of refining radiotherapy accuracy, the Raypilot® System is engineered to facilitate real-time motion management during treatments. This innovative system aids clinicians in improving pinpoint accuracy and potentially reducing adverse side effects that patients may experience during their cancer treatment.

During a conversation about the collaboration, Prof. Daniel Song from Johns Hopkins Medicine highlighted the significance of harnessing technologies that enable better intrafraction monitoring, noting that such advancements could revolutionize the precision of prostate radiotherapy treatments. This aligns with a broader objective of ensuring that treatments not only target tumors effectively but also spare healthy tissues as much as possible.

Additionally, Associate Professor Kai Ding underlined the importance of rigorously evaluating emerging technologies that augment treatment accuracy and enhance clinical workflows within radiation oncology. He believes that with continued assessment and validation, the Raypilot System could play a crucial role in the evolution of prostate cancer treatments.

Looking Ahead: Progressing Towards Broader Clinical Implementation

As the evaluation phase continues, Johns Hopkins Medicine has recognized potential advantages to integrating the Raypilot® System into its clinical processes, thereby supporting improved treatment accuracy. This initiative marks a substantial leap forward in the quest for advanced cancer therapies that prioritize patient well-being.

The collaboration between Micropos Medical and Johns Hopkins is poised to pave the way for broader clinical implementation of this innovative system. With the partnership progressing steadily, both institutions remain committed to fostering advancements in cancer treatment methods.

For further inquiries, Richard Forsberg, CEO of Micropos Medical AB, can be reached at Phone: 031-760 80 05 or via Email: [email protected].

In summary, this significant milestone achieved by Micropos Medical and Johns Hopkins marks a hopeful advancement in the treatment landscape for prostate cancer, propelled by innovative technology designed for improved patient outcomes and better quality of life.